<DOC>
	<DOCNO>NCT00335764</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose erlotinib , tipifarnib , temsirolimus give together sorafenib see well work treat patient recurrent glioblastoma multiforme gliosarcoma . Sorafenib , erlotinib , tipifarnib , temsirolimus may stop growth tumor cell block enzymes need cell growth . Sorafenib tipifarnib may also stop growth tumor cell block blood flow tumor . Giving sorafenib together erlotinib , tipifarnib , temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib Combined With Erlotinib , Tipifarnib , Temsirolimus Treating Patients With Recurrent Glioblastoma Multiforme Gliosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I Determine maximum tolerate dose ( MTD ) tipifarnib , erlotinib hydrochloride , temsirolimus combination fix dose sorafenib patient recurrent glioblastoma mutiforme gliosarcoma take enzyme-inducing antiepileptic drug . ( Phase I ) SECONDARY OBJECTIVES : I . Characterize safety profile doublet combination tipifarnib-sorafenib , erlotinib hydrochloride-sorafenib , temsirolimus-sorafenib patient recurrent glioblastoma multiforme gliosarcoma . ( Phase I II ) II . Characterize pharmacokinetics doublet combination , evaluate single-agent pharmacokinetics agent combination pharmacokinetics determine drug-drug interaction . ( Phase I II ) III . Determine efficacy doublet combination , term 6-month progression-free survival , patient recurrent glioblastoma multiforme gliosarcoma . ( Phase II ) IV . Determine efficacy doublet combination , term 12-month survival objective tumor response , patient recurrent glioblastoma multiforme gliosarcoma . ( Phase II ) TERTIARY OBJECTIVES : I . Perform exploratory correlative laboratory study examine tissue marker signal transduction pathway immunohistochemical analysis use tissue block obtain prior initiation protocol therapy , either time diagnosis subsequent tumor resection . ( Phase II ) II . Determine relationship tumor blood biomarkers clinical outcome patient treat combination target agent . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study tipifarnib , erlotinib hydrochloride , temsirolimus follow phase II open-label study . PHASE I : Patients sequentially assign 1 3 treatment group . GROUP 1 : Patients receive oral sorafenib twice daily oral erlotinib hydrochloride daily day 1-28 . GROUP 2 : Patients receive sorafenib group 1 . Patients also receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . GROUP 3 : Patients receive sorafenib group 1 . Patients also receive oral tipifarnib twice daily day 1-21 . In group , treatment repeat every 28 day 24 course absence disease progression unacceptable toxicity . In treatment group , cohorts 3-6 patient receive escalate dos erlotinib hydrochloride ( group 1 ) , temsirolimus ( group 2 ) , tipifarnib ( group 3 ) sequentially maximum tolerate dose ( MTD ) determine group . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity first course therapy . PHASE II : Patients receive sorafenib phase I . Patients also receive erlotinib hydrochloride , temsirolimus , tipifarnib phase I MTD determine phase I. Tissue collect prior surgery examine biomarkers immunohistochemistry ( patient enrol phase II portion study ) . Biomarkers examine include epidermal growth factor receptor , HER-2 , AKT , S6 ribosomal protein , Erk . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm intracranial glioblastoma multiforme gliosarcoma Evidence tumor progression MRI CT scan within past 14 day AND steroid dose stable ≥ 5 day Patients underwent prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis either positron emission tomography thallium scanning , MR spectroscopy , surgical documentation disease Recent resection recurrent progressive tumor allow Residual disease require Treatment number prior relapse , define disease progression initial therapy ( i.e. , radiotherapy without chemotherapy use initial treatment ) , allow ( phase I ) No 3 prior therapy ( initial therapy therapy 2 relapse ) ( phase II ) Each follow consider 1 relapse : Disease progression initial therapy ( i.e. , radiotherapy without chemotherapy use initial therapy ) Underwent surgical resection relapse disease receive anticancer therapy 12 week surgical resection AND underwent subsequent surgical resection Received prior therapy lowgrade glioma , follow surgical diagnosis glioblastoma Failed prior radiotherapy 15 unstained paraffin slide 1 tissue block must available original surgery , definitive surgery , surgery close initiation study ( phase II ) Karnofsky performance status 60100 % WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin normal Creatinine &lt; 1.5 mg/dL PT/INR ≤ 1.5 ( INR &lt; 3.0 patient anticoagulation therapy ) INR &lt; 1.1 time ULN ( patient prophylactic anticoagulation therapy [ lowdose warfarin ] ) Fasting cholesterol &lt; 350 mg/dL ( patient receive temsirolimus sorafenib ) Fasting triglyceride &lt; 400 mg/dL ( patient receive temsirolimus sorafenib ) Wellcontrolled hypertension ( e.g. , systolic blood pressure ≤ 140 mm Hg diastolic pressure ≤ 90 mm Hg ) allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week ( woman ) 3 month ( men ) completion study treatment No peripheral neuropathy &gt; grade 1 ( patient receive sorafenib tipifarnib ) No evidence bleed diathesis coagulopathy No history cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease ≥ 3 year No significant traumatic injury within past 21 day No active infection serious medical illness would preclude study treatment No condition would impair ability swallow pill ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation active peptic ulcer disease ) No HIV disease No allergies imidazole ( e.g. , clotrimazole , ketoconazole , miconazole econazole ) history allergic reaction attribute compound similar chemical biological composition tipifarnib ( patient receive sorafenib tipifarnib ) No disease would obscure toxicity dangerously alter drug metabolism Recovered prior therapy At least 7 day since prior noncytotoxic agent ( e.g. , interferon , tamoxifen , thalidomide , isotretinoin ) ( radiosensitizer count ) At least 14 day since prior vincristine At least 21 day since prior procarbazine major surgery At least 28 day since prior investigational agent cytotoxic therapy At least 42 day since prior nitrosoureas radiotherapy No prior sorafenib , AEE788 , vatalanib No prior surgical procedure affect absorption No prior tipifarnib , lonafarnib , agent target farnesyl transferase ( patient receive sorafenib tipifarnib ) No prior temsirolimus mTORtargeting agent ( phase II ) , rapamycin everolimus , Aktpathway inhibitor ( patient receive sorafenib temsirolimus ) No prior erlotinib hydrochloride , AEE788 , epidermal growth factor receptor target agent ( phase II ) ( patient receive sorafenib erlotinib hydrochloride ) No concurrent enzymeinducing antiepileptic drug ( e.g. , carbamazepine , oxcarbazepine , phenytoin , fosphenytoin , phenobarbital , primidone ) Dexamethasone allow No concurrent hepatic cytochrome p450 enzymeinducing anticonvulsant No concurrent investigational agent anticancer therapy , include chemotherapy , radiotherapy , hormonal therapy , immunotherapy No concurrent prophylactic filgrastim ( GCSF ) hematopoietic colonystimulating factor Fulldose anticoagulant allow provide follow criterion meet : Inrange INR ( 23 ) stable dose oral anticoagulant stable dose low molecular weight heparin No active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>